Test Article 1

MK-1654 (clesrovimab) met its primary efficacy endpoint of incidence of patients with RSV-associated medically attended lower respiratory infections (MALRI) through Day 150.

Good Neighbor Pharmacy customers from rural, suburban, and city areas reflect on the past year and discuss the future of independent pharmacy.

“If people think COVID is no big deal and decide to forgo vaccinations, they’re essentially doubling their risk of developing long COVID,” wrote investigators.

Updated vaccines are expected to be available in the coming months.

Global coverage for diphtheria, tetanus, and pertussis has reached its lowest point in 15 years.

Researchers are evaluating the safety, tolerability, and immunogenicity of shingles vaccine candidate Z-1018.